ME03058B - Antivirusna terapija - Google Patents

Antivirusna terapija

Info

Publication number
ME03058B
ME03058B MEP-2018-131A MEP13118A ME03058B ME 03058 B ME03058 B ME 03058B ME P13118 A MEP13118 A ME P13118A ME 03058 B ME03058 B ME 03058B
Authority
ME
Montenegro
Prior art keywords
antiviral therapy
antiviral
therapy
Prior art date
Application number
MEP-2018-131A
Other languages
German (de)
English (en)
French (fr)
Inventor
Mark Richard Underwood
Original Assignee
Viiv Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03058(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co
Publication of ME03058B publication Critical patent/ME03058B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MEP-2018-131A 2010-01-27 2011-01-24 Antivirusna terapija ME03058B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
EP15164931.6A EP2932970B1 (en) 2010-01-27 2011-01-24 Antiviral therapy

Publications (1)

Publication Number Publication Date
ME03058B true ME03058B (me) 2019-01-20

Family

ID=44319704

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2015-106A ME02182B (me) 2010-01-27 2011-01-24 TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN
MEP-2018-131A ME03058B (me) 2010-01-27 2011-01-24 Antivirusna terapija

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2015-106A ME02182B (me) 2010-01-27 2011-01-24 TERAPEUTSKA KOMBINACIJA KOJA SADRŽI DOLUTEGRAVIR, ABAKAVIR l LAMIVUDIN

Country Status (45)

Country Link
US (13) US20120295898A1 (me)
EP (6) EP2932970B1 (me)
JP (9) JP2013518107A (me)
KR (4) KR20170078868A (me)
CN (2) CN105311033B (me)
AP (1) AP3551A (me)
AU (1) AU2011209788C1 (me)
BR (1) BR112012018670A2 (me)
CA (4) CA2787691C (me)
CL (1) CL2012002080A1 (me)
CO (1) CO6602152A2 (me)
CR (1) CR20120423A (me)
CY (6) CY1116509T1 (me)
DK (4) DK2531027T3 (me)
DO (2) DOP2012000205A (me)
EA (4) EA032868B1 (me)
EC (1) ECSP12012106A (me)
ES (4) ES2688925T3 (me)
FI (2) FI3494972T3 (me)
FR (2) FR18C1043I2 (me)
HK (1) HK1250335A1 (me)
HR (4) HRP20240168T1 (me)
HU (6) HUE040554T2 (me)
IL (5) IL221007A (me)
LT (5) LT3494972T (me)
LU (2) LUC00090I2 (me)
MA (1) MA34002B1 (me)
ME (2) ME02182B (me)
MX (4) MX367938B (me)
MY (3) MY202778A (me)
NO (2) NO2932970T3 (me)
NZ (4) NZ627827A (me)
PE (2) PE20160180A1 (me)
PH (3) PH12012501537A1 (me)
PL (4) PL3127542T3 (me)
PT (4) PT3494972T (me)
RS (4) RS54123B1 (me)
SG (3) SG10201509476RA (me)
SI (4) SI2932970T1 (me)
SM (4) SMT201800594T1 (me)
TN (1) TN2012000376A1 (me)
TR (1) TR201807704T4 (me)
UA (1) UA105556C2 (me)
WO (1) WO2011094150A1 (me)
ZA (1) ZA201205586B (me)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
US10004721B2 (en) 2012-10-23 2018-06-26 Cipla Limited Pharmaceutical antiretroviral composition
CA2893843C (en) 2012-12-21 2018-09-04 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EP2956123A1 (en) 2013-02-18 2015-12-23 ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
EP2767272A1 (en) * 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (me) 2013-07-12 2018-07-21
DK3019503T3 (da) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
MX367057B (es) 2013-09-27 2019-08-02 Merck Sharp & Dohme Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih.
WO2015140569A1 (en) 2014-03-20 2015-09-24 Cipla Limited Pharmaceutical composition
EP3151920B1 (en) 2014-06-04 2025-08-06 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
NO2717902T3 (me) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
WO2016016279A1 (en) 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
WO2017029225A1 (en) * 2015-08-14 2017-02-23 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinations and uses treatments thereof
WO2018028841A1 (en) * 2016-08-12 2018-02-15 Sandoz Ag Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company Combination drug therapy
JP2020528413A (ja) * 2017-07-21 2020-09-24 ヴィーブ ヘルスケア カンパニー Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
KR20260015342A (ko) 2017-07-21 2026-02-02 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
AU2018347990B2 (en) * 2017-10-13 2021-09-09 Viiv Healthcare Company Bi-layer pharmaceutical tablet formulation
IL286328B1 (en) 2019-03-22 2026-04-01 Gilead Sciences Inc Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
CR20220418A (es) 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
CA3192145A1 (en) 2020-09-30 2022-04-07 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
JP7591155B2 (ja) 2021-01-19 2024-11-27 ギリアード サイエンシーズ， インコーポレイテッド 置換ピリドトリアジン化合物及びその使用
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023164293A1 (en) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Methods for viral infections
TWI856796B (zh) 2022-04-06 2024-09-21 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997049411A1 (en) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
AU3366899A (en) 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
CA2398640C (en) 2000-01-31 2011-06-14 Cook Biotech Incorporated Stent valves and uses of same
EE05400B1 (et) 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR040242A1 (es) 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
DE60303131T2 (de) 2002-06-27 2006-07-20 Medivir Ab Synergistische wechselwirkung von abacavir und alovudin
EA015145B1 (ru) * 2003-01-14 2011-06-30 Джилид Сайэнс, Инк. Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
EP1720856B1 (en) 2004-02-11 2013-08-14 GlaxoSmithKline LLC Hiv integrase inhibitors
JP4285353B2 (ja) 2004-03-05 2009-06-24 清水建設株式会社 化学物質放散度評価方法
ATE411030T1 (de) * 2004-04-14 2008-10-15 Gilead Sciences Inc Phosphonatanaloga von hiv- integrasehemmerverbindungen
EP2229945A1 (en) * 2004-05-21 2010-09-22 Japan Tobacco, Inc. Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
DE602005025977D1 (de) 2004-08-23 2011-03-03 Teva Pharma Kristalline form des ibandronat-natriums und herstellungsverfahren dafür
WO2006024668A1 (en) 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl] amino]benzonitrile
DE602005011031D1 (en) 2004-09-17 2008-12-24 Idenix Pharmaceuticals Inc Phosphoindole als hiv-inhibitoren
US7250421B2 (en) 2005-01-31 2007-07-31 University Of Georgia Research Foundation, Inc. Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
EP1853604A4 (en) 2005-03-04 2010-02-24 Smithkline Beecham Corp CHEMICAL COMPOUNDS
CN101212903B (zh) * 2005-04-28 2013-07-24 史密丝克莱恩比彻姆公司 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
PT1874117E (pt) 2005-04-28 2013-10-17 Shionogi & Co Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse
WO2006129134A1 (en) 2005-06-01 2006-12-07 Bioalliance Pharma Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents
CN101336107A (zh) * 2005-12-30 2008-12-31 吉里德科学公司 改善hiv整合酶抑制剂的药物动力学的方法
BRPI0620865A2 (pt) 2005-12-30 2011-11-29 Gilead Sciences Inc métodos para melhorar a farmacocinética de inibidores das integrases do hiv
CA2636436C (en) * 2006-01-20 2014-04-01 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tmc278
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
AU2007275690B2 (en) 2006-07-21 2013-01-17 Gilead Sciences, Inc. Antiviral protease inhibitors
ES2488922T3 (es) 2006-09-29 2014-09-01 Idenix Pharmaceuticals, Inc. Fosfoindoles enantiómeramente puros como inhibidores del HIV
EP4403221A3 (en) 2007-02-23 2024-10-09 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
WO2008103899A1 (en) 2007-02-23 2008-08-28 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
CN101784532B (zh) 2007-06-29 2014-10-22 韩国化学研究院 Hiv逆转录酶抑制剂
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
CN101796040A (zh) 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
US8426434B2 (en) * 2007-07-12 2013-04-23 Tibotec Pharmaceuticals Ltd. Crystalline form of 4-[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Ccr5 antagonists as therapeutic agents
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
PT2231628E (pt) 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
WO2009148600A2 (en) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Deuterated lysine-based compounds
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
KR101678563B1 (ko) 2008-12-11 2016-11-22 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
KR101733625B1 (ko) * 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
UA105556C2 (uk) 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法
CA2832066C (en) 2011-04-01 2023-04-18 The Medicines Company Short-acting dihydropyridines (clevidipine) for use in reducing stroke damage

Also Published As

Publication number Publication date
ES2688925T3 (es) 2018-11-07
US20160199379A1 (en) 2016-07-14
LTC3494972I2 (me) 2025-11-10
AU2011209788C1 (en) 2014-08-28
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
HK1250335A1 (en) 2018-12-14
HUS1800042I1 (hu) 2018-11-28
PT3494972T (pt) 2024-02-12
JP7724619B2 (ja) 2025-08-18
EP2932970A1 (en) 2015-10-21
EP2932970B1 (en) 2018-03-21
EP2531027B1 (en) 2015-05-06
MY202778A (en) 2024-05-21
PH12018502489A1 (en) 2020-06-15
EP3351249A1 (en) 2018-07-25
EP4316599A2 (en) 2024-02-07
PL3494972T3 (pl) 2024-05-27
TN2012000376A1 (en) 2014-01-30
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
EA202190473A2 (ru) 2021-06-30
US20170281636A1 (en) 2017-10-05
SI2531027T1 (sl) 2015-08-31
US20170119777A1 (en) 2017-05-04
EP3494972B1 (en) 2023-12-13
PE20121524A1 (es) 2012-12-03
MX367938B (es) 2019-09-12
CA2967453A1 (en) 2011-08-04
PH12016500195B1 (en) 2021-08-04
CA3003988C (en) 2020-01-07
PH12016500195A1 (en) 2016-12-05
CA2787691C (en) 2018-07-17
LT3494972T (lt) 2024-03-12
IL267658A (en) 2019-08-29
DK3494972T3 (da) 2024-01-29
RS54123B1 (sr) 2015-12-31
SG10201509476RA (en) 2015-12-30
FR18C1043I2 (fr) 2019-10-11
US20120295898A1 (en) 2012-11-22
PL3127542T3 (pl) 2019-03-29
US20210401850A1 (en) 2021-12-30
WO2011094150A1 (en) 2011-08-04
EA037601B1 (ru) 2021-04-20
MX367937B (es) 2019-09-12
KR101830715B1 (ko) 2018-04-04
US20150238496A1 (en) 2015-08-27
CN105311033A (zh) 2016-02-10
RS57728B1 (sr) 2018-12-31
JP2016145204A (ja) 2016-08-12
EP2531027A4 (en) 2013-07-03
PE20160180A1 (es) 2016-05-04
SMT202400063T1 (it) 2024-03-13
EA202190473A3 (ru) 2021-12-31
CY1116509T1 (el) 2017-03-15
DK2932970T3 (en) 2018-05-28
DK3127542T3 (en) 2018-11-12
IL245182A0 (en) 2016-06-30
PH12012501537A1 (en) 2018-02-07
LUC00346I1 (me) 2024-06-04
LTPA2018013I1 (lt) 2018-11-12
FR24C1024I1 (fr) 2024-07-26
IL257267B (en) 2019-08-29
RS65183B1 (sr) 2024-03-29
EA201892277A1 (ru) 2019-03-29
PT2531027E (pt) 2015-09-16
LT2932970T (lt) 2018-06-25
CA2787691A1 (en) 2011-08-04
LTPA2024516I1 (me) 2024-06-25
LTC2932970I2 (lt) 2022-04-25
CA3060290A1 (en) 2011-08-04
US20250017939A1 (en) 2025-01-16
CL2012002080A1 (es) 2012-11-30
PT3127542T (pt) 2018-11-26
KR20160111536A (ko) 2016-09-26
FR24C1024I2 (fr) 2025-06-27
CY1121040T1 (el) 2019-12-11
EP4316599A3 (en) 2024-04-10
CY1120457T1 (el) 2019-07-10
HRP20150770T1 (hr) 2015-08-28
MY207233A (en) 2025-02-07
KR101964923B1 (ko) 2019-04-02
US10426780B2 (en) 2019-10-01
CA3060290C (en) 2022-07-12
CY2018029I2 (el) 2019-07-10
IL221007A0 (en) 2012-09-24
AU2011209788A1 (en) 2012-08-16
JP2021091705A (ja) 2021-06-17
US20170079982A1 (en) 2017-03-23
DK2531027T3 (en) 2015-07-20
EP3127542A1 (en) 2017-02-08
EA032868B1 (ru) 2019-07-31
NZ627824A (en) 2016-02-26
MX2012008774A (es) 2012-08-17
MX356891B (es) 2018-06-19
AP3551A (en) 2016-01-18
DOP2021000147A (es) 2022-01-16
MA34002B1 (fr) 2013-02-01
BR112012018670A2 (pt) 2018-02-06
HRP20180855T1 (hr) 2018-06-29
KR20120128640A (ko) 2012-11-27
MY188334A (en) 2021-11-30
ECSP12012106A (es) 2013-05-31
NZ627826A (en) 2016-01-29
HK1209629A1 (en) 2016-04-08
NO2932970T3 (me) 2018-08-18
HUE065569T2 (hu) 2024-06-28
KR20180078358A (ko) 2018-07-09
US20180098992A1 (en) 2018-04-12
JP2023085431A (ja) 2023-06-20
DOP2012000205A (es) 2012-10-15
SI3127542T1 (sl) 2018-11-30
ES2969969T3 (es) 2024-05-23
ZA201205586B (en) 2014-01-29
PL2932970T3 (pl) 2018-08-31
US20180200254A1 (en) 2018-07-19
CO6602152A2 (es) 2013-01-18
KR101883750B1 (ko) 2018-07-31
FI3494972T3 (fi) 2024-03-01
ES2543066T3 (es) 2015-08-14
EA025176B1 (ru) 2016-11-30
SI3494972T1 (sl) 2024-03-29
SI2932970T1 (en) 2018-07-31
FR18C1043I1 (me) 2018-11-30
EP3127542B1 (en) 2018-08-22
TR201807704T4 (tr) 2018-06-21
US20200230147A1 (en) 2020-07-23
JP6268386B2 (ja) 2018-01-31
CA2967453C (en) 2018-07-17
LUC00090I2 (me) 2019-01-08
US11234985B2 (en) 2022-02-01
NZ601319A (en) 2014-08-29
IL281959A (en) 2021-05-31
KR20170078868A (ko) 2017-07-07
AU2011209788B2 (en) 2014-02-06
US20170216284A1 (en) 2017-08-03
NO2018036I1 (no) 2018-10-15
IL267658B (en) 2021-04-29
CY2018029I1 (el) 2019-07-10
EA201690872A2 (ru) 2016-08-31
IL245182B (en) 2018-04-30
EP3494972A1 (en) 2019-06-12
HRP20181531T1 (hr) 2018-11-16
HUE037812T2 (hu) 2018-09-28
IL281959B (en) 2021-12-01
PL2531027T3 (pl) 2016-01-29
SG10201707183TA (en) 2017-10-30
ES2670811T3 (es) 2018-06-01
HK1179522A1 (en) 2013-10-04
ME02182B (me) 2015-10-20
CR20120423A (es) 2012-11-22
CN102791129A (zh) 2012-11-21
LUC00346I2 (me) 2026-05-05
SMT201800290T1 (it) 2018-07-17
PT2932970T (pt) 2018-06-08
UA105556C2 (uk) 2014-05-26
CA3003988A1 (en) 2011-08-04
JP2018127473A (ja) 2018-08-16
EP2531027A1 (en) 2012-12-12
HUE026849T2 (en) 2016-08-29
FIC20240016I1 (fi) 2024-05-31
SMT201500177B (it) 2015-09-07
JP2025131664A (ja) 2025-09-09
IL257267A (en) 2018-03-29
LT3127542T (lt) 2018-11-26
NZ627827A (en) 2016-02-26
CY2024017I1 (el) 2025-05-09
CY2024017I2 (el) 2025-05-09
EA201690872A3 (ru) 2016-12-30
SMT201800594T1 (it) 2019-01-11
CN105311033B (zh) 2019-05-07
CY1126771T1 (el) 2025-05-09
CN102791129B (zh) 2015-09-30
US20160339033A1 (en) 2016-11-24
JP2013518107A (ja) 2013-05-20
EA201290583A1 (ru) 2013-04-30
JP2019167371A (ja) 2019-10-03
JP2017008087A (ja) 2017-01-12
JP2022071126A (ja) 2022-05-13
AP2012006445A0 (en) 2012-08-31
HUS2400017I1 (hu) 2024-06-28
HUE040554T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
HUS1800042I1 (hu) Antivirális terápia
IL222481A0 (en) Combination therapy
EP2552323A4 (en) COMBINATION THERAPY
IL226346A0 (en) Antiviral compounds
ZA201305897B (en) Combination therapy
ZA201400120B (en) Combination therapy
EP2585073A4 (en) ANTIVIRAL COMPOUNDS
EP2701744A4 (en) COMBINATION THERAPY
GB201005394D0 (en) Therapy
GB0905485D0 (en) Antiviral therapy
GB201016864D0 (en) Therapeutic methods
EP2629766A4 (en) COMBINATION THERAPY
ZA201207199B (en) Immune therapy
GB0908952D0 (en) Antiviral therapy
GB201004674D0 (en) Novel therapy
GB201021708D0 (en) Novel Therapeutic use
GB201114226D0 (en) Combination therapy
GB201018496D0 (en) Oro-tracheal defibrillator
PH32010000717S1 (en) Sidechair